[1]姜小庆,黄 鹏,胡 波,等.动脉栓塞药物洗脱微球的研究进展[J].介入放射学杂志,2023,32(10):1034-1039.
 JIANG Xiaoqing,HUANG Peng,HU Bo,et al.Research progress in drug-eluting beads used for transarterial chemoembolization[J].journal interventional radiology,2023,32(10):1034-1039.
点击复制

动脉栓塞药物洗脱微球的研究进展()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
32
期数:
2023年10
页码:
1034-1039
栏目:
综述
出版日期:
2023-10-31

文章信息/Info

Title:
Research progress in drug-eluting beads used for transarterial chemoembolization
作者:
姜小庆 黄 鹏 胡 波 赵东旭 徐 林 倪才方
Author(s):
JIANG Xiaoqing HUANG Peng HU Bo ZHAO Dongxu XU Lin NI Caifang.
Department of Interventional Radiology, First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province 215006, China
关键词:
【关键词】 经导管动脉化疗栓塞术 药物洗脱微球 肝细胞癌
文献标志码:
A
摘要:
【摘要】 药物洗脱微球经动脉化疗栓塞术(drug-eluting beads transarterial chemoembolization,DEB-TACE)是目前治疗不可切除肝恶性肿瘤的常用方法之一,通过动脉内注射药物洗脱微球达到栓塞肿瘤供血动脉和杀伤肿瘤细胞的作用。本文系统地阐述用于经动脉化疗栓塞术的不可生物降解和可生物降解药物洗脱微球的最新进展,讨论不同药物的载药能力和载药方式,如细胞毒性药物和具有不同理化性质的抗血管生成药物等,并对药物在体外或体内的释放动力学以及在靶组织和非靶组织中的分布进行详细的介绍。

参考文献/References:

[1] Bzeizi KI,Arabi M,Jamshidi N,et al. Conventional transarterial chemoembolization versus drug- eluting beads in patients with hepatocellular carcinoma: a systematic review and meta- analysis[J]. Cancers(Basel), 2021, 13: 6172.
[2] Nouri YM, Kim JH, Yoon HK, et al. Update on transarterial chemoembolization with drug- eluting microspheres for hepato-cellular carcinoma[J]. Korean J Radiol, 2019, 20: 34- 49.
[3] Melchiorre F, Patella F, Pescatori L, et al. DEB- TACE: a standard review[J]. Future Oncol, 2018, 14: 2969- 2984.
[4] Mikhail AS, Negussie AH, Mauda- Havakuk M, et al. Drug- eluting embolic microspheres: state- of- the- art and emerging clinical applications[J]. Expert Opin Drug Deliv, 2021, 18: 383- 398.
[5] Hu J, Albadawi H, Chong BW, et al. Advances in biomaterials and technologies for vascular embolization[J]. Adv Mater,2019,31:e1901071.
[6] Fuchs K,Duran R,Denys A,et al. Drug- eluting embolic micro-spheres for local drug delivery: state of the art[J]. J Control Release, 2017, 262:127-138.
[7] Yang Y, Yang R, Zhang B, et al. Preparation and investigation of a novel iodine- based visible polyvinyl alcohol embolization material[J]. J Interv Med, 2022, 5: 72- 78.
[8] 龚元川,邵国良. 载药微球的理化特性及其在肝癌介入治疗中的应用进展[J]. 介入放射学杂志, 2022, 31:616- 622.
[9] de Baere T, Plotkin S, Yu R, et al. An in vitro evaluation of four types of drug- eluting microspheres loaded with doxorubicin[J]. J Vasc Interv Radiol, 2016, 27: 1425- 1431.
[10] Guiu B, Hincapie G, Thompson L, et al. An in vitro evaluation of four types of drug- eluting embolics loaded with idarubicin[J]. J Vasc Interv Radiol, 2019, 30: 1303- 1309.
[11] Zurstrassen CE, Gireli LPDO, Tyng CJ, et al. Safety and efficacy of HepaSphere 50- 100 μm in the treatment of hepatocellular carcinoma[J]. Minim Invasive Ther Allied Technol, 2017, 26: 212- 219.
[12] Namur J, Citron SJ, Sellers MT, et al. Embolization of hepatocellular carcinoma with drug- eluting beads: doxorubicin tissue concentration and distribution in patient liver explants[J]. J Hepatol, 2011, 55: 1332- 1338.
[13] Wang YX, de Baere T, Idee JM, et al. Transcatheter embolization therapy in liver cancer: an update of clinical evidences[J]. Chin J Cancer Res, 2015, 27: 96- 121.
[14] Hong K, Khwaja A, Liapi E, et al. New intra- arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer[J]. Clin Cancer Res, 2006, 12: 2563- 2567.
[15] Lammer J, Malagari K, Vogl T, et al. Prospective randomized study of doxorubicin- eluting- bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study[J]. Cardiovasc Intervent Radiol, 2010, 33: 41- 52.
[16] Zhao GS, Liu S, Zhang YW, et al. Irinotecan eluting beads- transarterial chemoembolization using Callispheres?誖 microspheres is an effective and safe approach in treating unresectable colorectal cancer liver metastases[J]. Ir J Med Sci, 2022, 191: 1139- 1145.
[17] Peng Z,Cao G,Hou Q,et al. The comprehensive analysis of efficacy and safety of CalliSpheres?誖drug- eluting beads transarterial chemoembolization in 367 liver cancer patients: a multiple- center, cohort study[J]. Oncol Res, 2020, 28: 249- 271.
[18] Liapi E,Geschwind JF. Transcatheter arterial chemoembolization for liver cancer: is it time to distinguish conventional from drug- eluting chemoembolization?[J]. Cardiovasc Intervent Radiol, 2011, 34: 37- 49.
[19] Sheth RA, Hesketh R, Kong DS, et al. Barriers to drug delivery in interventional oncology[J]. J Vasc Interv Radiol, 2013, 24: 1201- 1207.
[20] Rimassa L,Danesi R,Pressiani T,et al. Management of adverse events associated with tyrosine kinase inhibitors: improving outcomes for patients with hepatocellular carcinoma[J]. Cancer Treat Rev, 2019, 77: 20- 28.
[21] Ikeda M,Okusaka TKI,Mitsunaga S,et al. Safety and pharmaco- kinetics of lenvatinib in patients with advanced hepatocellular carcinoma[J]. Clin Cancer Res, 2016, 22: 1385- 1394.
[22] Zhu XD, Tang ZY, Sun HC. Targeting angiogenesis for liver cancer: past, present, and future[J]. Genes Dis,2020,7:328- 335.
[23] Huang A,Yang XR,Chung WY,et al. Targeted therapy for hepa- tocellular carcinoma[J]. Signal Transduct Target Ther, 2020, 5: 146.
[24] Fuchs K, Bize PE, Denys A, et al. Sunitinib- eluting beads for chemoembolization: methods for in vitro evaluation of drug release[J]. Int J Pharm, 2015, 482: 68- 74.
[25] Sakr OS, Berndt S, Carpentier G, et al. Arming embolic beads with anti- VEGF antibodies and controlling their release using LbL technology[J]. J Control Release, 2016, 224: 199- 207.
[26] Ashrafi K, Tang Y, Britton H, et al. Characterization of a novel intrinsically radiopaque drug- eluting bead for image- guided therapy: DC Bead LUMITM[J]. J Control Release, 2017, 250: 36- 47.
[27] Minici R, Ammendola M, Manti F, et al. Safety and efficacy of degradable starch microspheres transcatheter arterial chemoem- bolization(DSM- TACE) in the downstaging of intermediate- stage hepatocellular carcinoma(HCC) in patients with a child- pugh score of 8- 9[J]. Front Pharmacol, 2021, 12: 634087.
[28] Ludwig JM, Iezzi R, Theysohn JM, et al. European multicenter study on degradable starch microsphere TACE: the digestible way to conquer HCC in patients with high tumor burden[J]. Cancers(Basel), 2021, 13: 5122.
[29] Gross A, Albrecht T. Transarterial chemoembolisation(TACE) with degradable starch microspheres(DSM) and anthracycline in patients with locally extensive hepatocellular carcinoma (HCC): safety and efficacy[J]. Cardiovasc Intervent Radiol, 2020, 43: 402- 410.
[30] Owen RJ, Nation PN, Polakowski R, et al. A preclinical study of the safety and efficacy of OcclusinTM 500 artificial embolization device in sheep[J]. Cardiovasc Intervent Radiol, 2012, 35: 636- 644.
[31] Stechele M, Wittgenstein H, Stolzenburg N, et al. Novel MR- visible, biodegradable microspheres for transcatheter arterial embolization: experimental study in a rabbit renal model[J]. Cardiovasc Intervent Radiol, 2020, 43: 1515- 1527.
[32] Choi JW, Park JH, Cho HR, et al. Sorafenib and 2,3,5- triiodobenzoic acid- loaded imageable microspheres for transarterial embolization of a liver tumor[J]. Sci Rep, 2017, 7: 554.
[33] Hagan A, Phillips GJ, Macfarlane WM, et al. Preparation and characterisation of vandetanib- eluting radiopaque beads for locoregional treatment of hepatic malignancies[J]. Eur J Pharm Sci, 2017, 101: 22- 30.
[34] Alpdemir S,Vural T,Kara G,et al. Magnetically responsive, sorafenib loaded alginate microspheres for hepatocellular carcinoma treatment[J]. IET Nanobiotechnol,2020 ,14:617- 622.
[35] Weng L, Rostamzadeh P, Nooryshokry N, et al. In vitro and in vivo evaluation of biodegradable embolic microspheres with tunable anticancer drug release[J]. Acta Biomater, 2013, 9: 6823- 6833.
[36] Weng L, Le HC, Lin J, et al. Doxorubicin loading and eluting characteristics of bioresorbable hydrogel microspheres: in vitro study[J]. Int J Pharm, 2011, 409: 185- 193.
[37] Weng L, Seelig D, Rostamzadeh P, et al. Calibrated bioresorbable microspheres as an embolic agent: an experimental study in a rabbit renal model[J]. J Vasc Interv Radiol , 2015, 26: 1887- 1894.e1.
[38] Weng L,Le HC,Talaie R,et al. Bioresorbable hydrogel microspheres for transcatheter embolization: preparation and in vitro evaluation[J]. J Vasc Interv Radiol, 2011, 22: 1464- 1470.e2.
[39] Jordan O,Denys A,De Baere T,et al. Comparative study of chemo-embolization loadable beads: in vitro drug release and physical properties of DC bead and hepasphere loaded with doxorubicin and irinotecan[J]. J Vasc Interv Radiol, 2010, 21: 1084- 1090.
[40] Louguet S,Verret V,Bedouet L,et al. Poly(ethylene glycol) methacrylate hydrolyzable microspheres for transient vascular embolization[J]. Acta Biomater, 2014, 10: 1194- 1205.
[41] Lewis AL,Gonzalez MV,Leppard SW,et al. Doxorubicin eluting beads- 1: effects of drug loading on bead characteristics and drug distribution[J]. J Mater Sci Mater Med, 2007, 18: 1691- 1699.
[42] Bedouet L, Verret V, Louguet S, et al. Anti- angiogenic drug delivery from hydrophilic resorbable embolization microspheres: an in vitro study with sunitinib and bevacizumab[J]. Int J Pharm, 2015, 484: 218- 227.
[43] Wang YJ, Molin DGM, Sevrin C, et al. In vitro and in vivo evaluation of drug- eluting microspheres designed for transarterial chemoembolization therapy[J]. Int J Pharm, 2016, 503: 150- 162.
[44] Li X,Yu H,Huang Y,et al. Preparation of microspheres encapsulating sorafenib and catalase and their application in rabbit VX2 liver tumor[J]. Biomed Pharmacother, 2020, 129: 110512.
[45] Li X,He G, Su F, et al. Regorafenib- loaded poly(lactide- co- glycolide)microspheres designed to improve transarterial chemo-embolization therapy for hepatocellular carcinoma[J]. Asian J Pharm Sci, 2020, 15: 739- 751.

相似文献/References:

[1]陈昆山,张 靖,申 刚,等.经导管动脉化疗栓塞在中晚期肝胚细胞瘤术前的临床应用[J].介入放射学杂志,2016,(03):220.
 CHEN Kun- shan,ZHANG Jing,SHEN Gang,et al.Clinical application of preoperative transcatheter arterial chemoembolization in treating advanced hepatoblastomas[J].journal interventional radiology,2016,(10):220.
[2]于 翔,成思航,曹 磊,等.术前全身免疫炎症指数与DEB-TACE治疗肝癌患者预后相关性分析[J].介入放射学杂志,2021,30(05):461.
 YU Xiang,CHENG Sihang,CAO Lei,et al.Analysis of the correlation between the preoperative systemic immune inflammatory index and the prognosis in liver cancer patients receiving transarterial chemoembolization with CalliSpheres drug-eluting beads[J].journal interventional radiology,2021,30(10):461.
[3]张 雯,周永杰,颜志平.再论精细TACE[J].介入放射学杂志,2021,30(10):971.
 ZHANG Wen,ZHOU Yongjie,YAN Zhiping..Further discussion on the precision TACE therapy[J].journal interventional radiology,2021,30(10):971.
[4]于 翔,谢 坪,李金泽,等.预测DEB-TACE治疗肝细胞肝癌术后生存率的放射组学列线图[J].介入放射学杂志,2022,31(01):39.
 YU Xiang,XIE Ping,LI Jinze,et al.Application of CT radiomics nomogram model in predicting the survival time of patients with hepatocellular carcinoma after receiving drug- eluting beads transarterial chemoembolization[J].journal interventional radiology,2022,31(10):39.
[5]夏子聪,赵 辉.改善经导管动脉化疗栓塞术疗效的临床及基础研究进展[J].介入放射学杂志,2023,32(07):705.
 XIA Zicong,ZHAO Hui..Advances in clinical and fundamental researches for improving the efficacy of transcatheter arterial chemoembolization[J].journal interventional radiology,2023,32(10):705.
[6]张学贤,丁雨寒,李 威,等.经导管动脉化疗栓塞联合仑伐替尼及卡瑞利珠单抗治疗中晚期肝细胞癌临床效果[J].介入放射学杂志,2024,33(01):57.
 ZHANG Xuexian,DING Yuhan,LI Wei,et al.Clinical efficacy of transcatheter arterial chemoembolization combined with lenvatinib and camrelizumab in the treatment of advanced hepatocellular carcinoma[J].journal interventional radiology,2024,33(10):57.

备注/Memo

备注/Memo:
(收稿日期:2022- 07- 14)
(本文编辑:茹 实)
更新日期/Last Update: 2023-10-31